This research critiques the Hatch-Waxman Act, arguing it enables pharmaceutical companies to extend monopolies through “evergreening,” delaying cheaper generics. It proposes legal reforms to restore balance between innovation and access, strengthen FDA oversight, and reduce drug costs, ensuring life-saving medications remain affordable for patients across the United States.